...
首页> 外文期刊>The cancer journal >Cellular vaccine approaches.
【24h】

Cellular vaccine approaches.

机译:细胞疫苗方法。

获取原文
获取原文并翻译 | 示例

摘要

Therapeutic cancer vaccines aim to generate immunologic targeting of cancer cells through the induction of effective cellular and antibody-mediated responses specific for antigens selectively expressed by the tumor. Exploiting the adaptive immune system as a targeted tool against cancer is appealing in its capacity for exact specificity and avoidance of unintended tissue damage seen by other conventional agents such as chemotherapy. There are a multitude of challenges to designing effective vaccine strategies. The components of a vaccine strategy start with the challenges of selecting immunogenic, tumor-specific antigen targets, choosing a platform with which to deliver the antigens, and enhancing the immunostimulatory context in which the vaccines are delivered. Although understanding the components of effective T-cell activation is essential, successful effector T cells can only be produced if there is also an understanding of the natural processes that tumors exploit to down-modulate active immune responses. These processes are normally used to down-regulate excessive tissue-destructive immune responses against infectious agents once the infecting agent is cleared or to prevent autoimmunity. Advances in molecular and cellular technologies continue to provide insights into the regulation of immune responses both to infectious agents and to cancer that may be manipulated to tip the balance in favor of tumor regression over immune tolerance. This review focuses primarily on cellular vaccines. For the purpose of this review, cellular vaccines are defined as vaccines that use whole cells or cell lysates either as the source of antigens or the platform in which to deliver the antigens. Dendritic cell (DC)-based vaccines focus on ex vivo antigen delivery to DCs. Other platforms such as GVAX (tumor cells genetically engineered to produce granulocyte-macrophage colony-stimulating factor) aim to deliver tumor antigens in vivo in an immune stimulatory context to endogenous DCs. Because data continue to emerge regarding the importance of the maturation status of DCs and the importance of the particular subset of DCs being targeted, these insights will be integrated into vaccine strategies that are likely to produce more effective vaccines.
机译:治疗性癌症疫苗旨在通过诱导对肿瘤选择性表达的抗原特异的有效细胞和抗体介导的反应,来产生针对癌细胞的免疫学靶向。利用适应性免疫系统作为针对癌症的靶向工具,其在准确特异性和避免其他常规药物(如化学疗法)所见的意外组织损伤方面的能力具有吸引力。设计有效的疫苗策略存在许多挑战。疫苗策略的组成部分始于以下挑战:选择免疫原性,肿瘤特异性抗原靶标,选择用于递送抗原的平台以及增强疫苗递送的免疫刺激环境。尽管了解有效T细胞活化的组成要素至关重要,但只有对肿瘤利用天然过程来下调主动免疫反应的理解有所了解,才能成功产生效应T细胞。一旦感染剂被清除,这些过程通常用于下调针对感染剂的过度的组织破坏性免疫反应或防止自身免疫。分子和细胞技术的进步继续提供对针对传染原和癌症的免疫反应调控的见解,可以通过操纵这些平衡来促进平衡,从而有利于肿瘤消退而不是免疫耐受。这篇评论主要集中在细胞疫苗上。为了本综述的目的,细胞疫苗被定义为使用全细胞或细胞裂解物作为抗原来源或在其中递送抗原的平台的疫苗。基于树突细胞(DC)的疫苗专注于离体抗原向DC的递送。其他平台,例如GVAX(经过基因工程改造以产生粒细胞-巨噬细胞集落刺激因子的肿瘤细胞)旨在在体内以免疫刺激的方式将肿瘤抗原递送至内源性DC。由于有关DC的成熟状态的重要性和DC特定亚群的重要性的数据不断涌现,因此这些见解将被整合到可能产生更有效疫苗的疫苗策略中。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号